Chapter 5: Lessons Learned in Understanding Dual Variable Domain-Ig (DVD-Ig) Structural Complexity to Select DVD-Ig Lead and Therapeutic Candidates

  • W. Blaine Stine
  • Dana I. FilotiEmail author
  • Tariq Ghayur
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 35)


The successful delivery of any novel biotherapeutic to patients requires the translation of discovery concepts to clinical enablement. Based on our experience in the development of mAb therapeutics and in evaluating 1000s of DVD-Ig molecules, in this chapter we will briefly discuss (i) critical aspects considered in developing the DVD-Ig platform and (ii) the lessons learned in selecting therapeutic grade DVD-Ig molecules, specifically with regard to how various structural components impact (a) structural-functional properties, (b) biophysical and biochemical properties, (c) PK profiles, and (d) manufacturability (i.e., expression, formulation, etc.).


DVD-Ig Drug-like properties Aggregation Thermal stability Colloidal stability Posttranslational modifications Variable domain, Linker 


  1. 1.
    Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212.CrossRefGoogle Scholar
  2. 2.
    Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu R-R, Santora L, Davis-Taber R, Kunes Y, Fung E, Schwartz A, Sakorafas P, Gu J, Tarcsa E, Murtaza A, Ghayur T. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007;25:1290–7.CrossRefGoogle Scholar
  3. 3.
    Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules. MAbs. 2009;1:339–47.CrossRefGoogle Scholar
  4. 4.
    Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L, Fang C, Zheng L, Zhang X, Liang P, Zhang X, Li B, Guo Y. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett. 2010;299:130–6.CrossRefGoogle Scholar
  5. 5.
    Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, et al. Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities. PLoS One. 2014;9(5):e97292. Scholar
  6. 6.
    Gu J, Yang J, Chang Q, Liu Z, Ghayur T, Gu J. Identification of anti-EGFR and anti-ErbB3 dual variable domains immunoglobulin (DVD-Ig) proteins with unique activities. PLoS One. 2015;10(5):e0124135. Scholar
  7. 7.
    Bardwell P, Staron M, Liu J, Tao Q, Scesney S, Bukofzer G, Rodriguez L, Choi C-H, Wang J, Chang Q, Dong F, Donawho C, Wang J, Grinnell C, Tarcsa E, Hutchins C, Ghayur T, Gu J. Potent and conditional redirected T cell killing of tumor cells using half DVD-Ig. Protein Cell. 2018;9:121–9.CrossRefGoogle Scholar
  8. 8.
    Karaoglu-Hanzatian D, Schwartz A, Gizatullin F, Erickson J, Deng K, Villanueva R, Stedman C, Harris C, Ghayur T, Goodearl A. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration. MAbs. 2018;10:765–77.CrossRefGoogle Scholar
  9. 9.
    Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, Suzuki T, Adachi H, Miyazaki T, Ishii S, Kamata-Sakurai M, Iida T, Harada A, Esaki K, Funaki M, Moriyama C, Tanaka E, Mikuchi Y, Wakabayashi T, Wada M, Goto M, Toyoda T, Ueyama A, Suzuki S, Haraya K, Tachibana T, Kawabe Y, Shima M, Yoshioka A, Hattori K. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570–4.CrossRefGoogle Scholar
  10. 10.
    Wec A, Nyakatura E, Herbert A, Howell K, Holtsberg F, Bakken R, Mittler E, Christin J, Shulenin S, Jangra R, Bharrhan S, Kuehne A, Bornholdt Z, Flyak A, Ollmann Saphire E, Crowe J Jr, Aman J, Dye J, Lai J, Chandran K. A “Trojan horse” bispecific antibody strategy for broad protection against ebolaviruses. Science. 2016;354:350–4. Scholar
  11. 11.
    Deora A, Hegde S, Lee J, Choi C-H, Chang Q, Lee C, Eaton L, Tang H, Wang D, Lee D, Michalak M, Tomlinson M, Tao Q, Gaur N, Harvey B, McLoughlin S, Labkovsky B, Ghayur T. Transmembrane TNF-dependent uptake of anti-TNF antibodies. MAbs. 2017;9:680–95.CrossRefGoogle Scholar
  12. 12.
    Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208.CrossRefGoogle Scholar
  13. 13.
    Tarcsa E, Fraunhofer W, Ghayur T, Salfeld J, Gu J. Dual-variable domain immunoglobulin (DVD-Ig™) technology: a versatile, novel format for the next generation of dual-targeting biologics. In: Kontermann R, editor. Bispecific antibodies. Berlin, Heidelberg: Springer; 2011.Google Scholar
  14. 14.
    Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel. 2010;23:549–57; PMID:20457695. Scholar
  15. 15.
    Correia I, Sung J, Burton R, Jakon C, Carragher B, Ghayur T, Radziejewski C. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs. 2013;5:364–72.CrossRefGoogle Scholar
  16. 16.
    Jakob C, Edalji R, Judge R, DiGiammarino E, Li Y, Gu J, Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs. 2013;5:358–63.CrossRefGoogle Scholar
  17. 17.
    Siedler M, Kumar V, Chari R, Saluja S, Fraunhofer W. Development of drug product formulations: molecular design and early candidates screening. In: Jameel F, Hershenson S, Khan M, Martin-Moe S, editors. Quality by design for biopharmaceutical drug product development. AAPS advances in the pharmaceutical sciences series, vol. 18. New York: Springer; 2015.Google Scholar
  18. 18.
    Krah S, Kolmar H, Becker S, Zielonka S. Engineering IgG-like bispecific antibodies—an overview. Antibodies. 2018;7:28.CrossRefGoogle Scholar
  19. 19.
    Hermeling S, Crommelin DJA, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21:897–903. Scholar
  20. 20.
    Gokarn YR, Fesinmeyer RM, Saluja A, Razinkov V, Chase SF, Laue TM, Brems DN. Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutions. Protein science: a publication of the protein. Society. 2011;20(3):580–7.Google Scholar
  21. 21.
    Invernizzi G, Papaleo E, Sabate R, Ventura S. Protein aggregation: mechanisms and functional consequences. Int J Biochem Cell Biol. 2012;44:1541–54. Scholar
  22. 22.
    Piedmonte DM, Gu JH, Brych SR, Goss MM. Practical considerations for high concentration protein formulations. In: Warne N, Mahler HC, editors. Challenges in protein product development. AAPS advances in the pharmaceutical sciences series, vol. 38. Cham: Springer; 2018.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2020

Authors and Affiliations

  • W. Blaine Stine
    • 1
  • Dana I. Filoti
    • 2
    Email author
  • Tariq Ghayur
    • 3
  1. 1.Discovery BiologicsAbbVie Bioresearch CenterWorcesterUSA
  2. 2.NBE Analytical R&DAbbVie Bioresearch CenterWorcesterUSA
  3. 3.Discovery ImmunologyAbbVie Bioresearch CenterWorcesterUSA

Personalised recommendations